These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 18586363)
41. Immunogenicity of anthrax recombinant peptides and killed spores in goats and protective efficacy of immune sera in A/J mouse model. Ndumnego OC; Koehler SM; Crafford JE; Beyer W; van Heerden H Sci Rep; 2018 Nov; 8(1):16937. PubMed ID: 30446695 [TBL] [Abstract][Full Text] [Related]
42. The anthrax vaccine: no new tricks for an old dog. Bienek DR; Loomis LJ; Biagini RE Hum Vaccin; 2009 Mar; 5(3):184-9. PubMed ID: 19270504 [TBL] [Abstract][Full Text] [Related]
43. Efficacy of recombinant anthrax vaccine against Bacillus anthracis aerosol spore challenge: preclinical evaluation in rabbits and Rhesus monkeys. Chawla A; Midha S; Bhatnagar R Biotechnol J; 2009 Mar; 4(3):391-9. PubMed ID: 19296443 [TBL] [Abstract][Full Text] [Related]
44. Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys. Whipple EC; Ditto AH; Shanahan RS; Gatesman JJ; Little SF; Taylor RP; Lindorfer MA Mol Immunol; 2007 Jan; 44(4):377-88. PubMed ID: 16631928 [TBL] [Abstract][Full Text] [Related]
45. A two-stage, multilevel quality control system for serological assays in anthrax vaccine clinical trials. Soroka SD; Schiffer JM; Semenova VA; Li H; Foster L; Quinn CP Biologicals; 2010 Nov; 38(6):675-83. PubMed ID: 20875951 [TBL] [Abstract][Full Text] [Related]
47. Gorse GJ, et al. "Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial" [Vaccine 24 (2006) 5950-5959]. Zink TK Vaccine; 2007 Apr; 25(15):2766-7. PubMed ID: 17224206 [TBL] [Abstract][Full Text] [Related]
48. Immunological dynamics in response to two anthrax vaccines in mice. Lü J; He R; Dong M; Zhang L; Wang X Sci China C Life Sci; 2008 Oct; 51(10):872-8. PubMed ID: 18815750 [TBL] [Abstract][Full Text] [Related]
49. Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis. Ionin B; Hopkins RJ; Pleune B; Sivko GS; Reid FM; Clement KH; Rudge TL; Stark GV; Innes A; Sari S; Guina T; Howard C; Smith J; Swoboda ML; Vert-Wong E; Johnson V; Nabors GS; Skiadopoulos MH Clin Vaccine Immunol; 2013 Jul; 20(7):1016-26. PubMed ID: 23658392 [TBL] [Abstract][Full Text] [Related]
55. Results of a safety and immunogenicity study of an early-stage investigational rPA102 vaccine as compared to the FDA licensed anthrax vaccine (anthrax vaccine adsorbed (AVA. BioThrax)). Hannesschlager JR Vaccine; 2007 Apr; 25(17):3247. PubMed ID: 17234308 [No Abstract] [Full Text] [Related]
56. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. Crotty S; Aubert RD; Glidewell J; Ahmed R J Immunol Methods; 2004 Mar; 286(1-2):111-22. PubMed ID: 15087226 [TBL] [Abstract][Full Text] [Related]
57. Genetic immunization with GPI-anchored anthrax protective antigen raises combined CD1d- and MHC II-restricted antibody responses by natural killer T cell-mediated help. Midha S; Bhatnagar R Vaccine; 2009 Mar; 27(11):1700-9. PubMed ID: 19195490 [TBL] [Abstract][Full Text] [Related]
58. Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism. Bouzianas DG Expert Rev Anti Infect Ther; 2007 Aug; 5(4):665-84. PubMed ID: 17678429 [TBL] [Abstract][Full Text] [Related]
59. Feasibility of the use of ELISA in an immunogenicity-based potency test of anthrax vaccines. Jiménez-Alberto A; Parreiras P; Castelán-Vega J; Sirota L; Arciniega J Biologicals; 2011 Jul; 39(4):236-41. PubMed ID: 21664832 [TBL] [Abstract][Full Text] [Related]
60. Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial. Pondo T; Rose CE; Martin SW; Keitel WA; Keyserling HL; Babcock J; Parker S; Jacobson RM; Poland GA; McNeil MM Vaccine; 2014 Jun; 32(28):3548-54. PubMed ID: 24768633 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]